Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs).

The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Please note, this stock reported earnings on Thursday, March 14th.